Account
Concerned about the need to fight antibiotic resistance and possible bioterrorist attacks, the U.S. government will give drug maker GlaxoSmithKline PLC (GSK, GSK.LN) up to $200 million over the next five years to help fund research into new antibiotics.The emergence of so-called superbugs--new bacteria that are resistant to existing antibiotics--has spurred grave concern among public-health officials worldwide and heightened the need for new antibiotics. U.S. officials are also keen to have new antibiotics in hand to fight any lethal bugs that could be deployed in a bioterrorist attack. But many drug companies have stopped working in the antibiotic field because they consider the potential profits to be too low.Under the deal, Glaxo, which still has an antibiotic research group, will receive an initial $40 million over 18 months from the Biomedical Advanced Research and Development Authority, or BARDA, a unit of the Department of Health and Human Services that funds development of new ...
Siri may be able to tell you the capital of Kazakhstan and show you the city’s weather forecast -- but her descendents will be able to book the flight that gets you ...
Wells Fargo Funds Management Chief Equity Strategist John Manley on why he has a bullish outlook for the markets and what sectors investors should add to their portfolio.
Dr. Marc Siegel, FNC senior medical contributor, on recent threats to public health including orange juice imports being halted, and a new strain of swine flu .
GlaxoSmithKline's sales returned to growth in the third quarter as Britain's biggest drugmaker put patent expiries and a collapse in revenue from troubled diabetes p...
By Katie ReidZURICH (Reuters) - Swiss drugmaker Roche Holding AG <ROG.VX> raised its full-year earnings target for 2011 on Thursday as cost-cutting protected its fir...
Lessons from the Japanese earthquake teach that no business is immune to potential disaster. Here's how you can prepare for the worst and survive with the best.No ma...
FNC medical contributor Dr. Marc Siegel on the debate over links between cell phone use and cancer.
Every day, it seems, we're bombarded by things we need to fear: terrorism, economic Armageddon, swine flu, etc. With a full plate of peril perpetually besetting our ...
Barry, a 47-year-old from Fort Lauderdale, Fla., works as a D.J. to pay his mortgage. He has a three- bedroom, one-bathroom ranch that may be modest, but is symbolic...
By Katie ReidZURICH (Reuters) - Novartis AG <NOVN.VX> is likely to be the latest drugmaker to show it too has been hit by a collapse in sales of pandemic flu medicin...
By Ben HirschlerLONDON (Reuters) - Roche <ROG.VX> is set to kick off the Big Pharma reporting season with a fall in sales on Thursday as a strong Swiss franc, weak d...
Imogen Lloyd Webber and Bernard McGuirk discuss the decision by William and Kate to invite former boyfriends and girlfriends to the royal ceremony.
Bowing to years of pressure, Swiss drug maker Roche Holding AG (RO.EB) said Friday it would release clinical trial data for its blockbuster Tamiflu influenza treatme...
Swiss drug maker Roche Holding AG (ROG.VX) said Friday it has agreed to give outside researchers access to all its clinical trial data for Tamiflu, a blockbuster inf...
Roche Holding AG (ROG.VX) said Tuesday it would provide greater access to the results of its clinical trials, bowing to pressure from outside researchers seeking to ...
A high body count is not the only meaningful number attached to a pandemic. The potential cost of a global outbreak of the flu or some other highly contagious diseas...
Dr. Marc Siegel on efforts to fight the flu virus this year.
Dr. Marc Siegel on the benefits of getting a flu shot this year.
Exit presidential elections. Enter looming budget crisis. And once again, a disconnect between how Washington and Wall Street see the world could cause pain for inve...